

UNITED STATES PATENT AND TRADEMARK OFFICE

Onited	states latent and llademark Office	
Address	COMMISSIONER OF PATENTS AND TRADEMARKS	
	Washington, D C 20231	
	www.usoto.gov	

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/897,412	07/03/2001	Richard J. Davis	620-148	8317
7:	590 03/13/2003			
NIXON & VANDERHYE P.C.			EXAMINER	
8th Floor 1100 North Gle	• • • • • • • • • • • • • • • • • • • •		NICHOLS, CHI	RISTOPHER J 9
Arlington, VA	22201		ART UNIT	PAPER NUMBER
			1647	

DATE MAILED: 03/13/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
Office Auti	09/897,412	DAVIS ET AL.	
Office Action Summary	Examiner	Art Unit	
	Christopher Nichols, Ph.D.	1647	
The MAILING DATE of this communication ap	pears on the cover sheet with	h the correspondence address	
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a rep - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute - Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b). Status	136(a). In no event, however, may a repolly within the statutory minimum of thirty will apply and will expire SIX (6) MONTA	(30) days will be considered timely NEONED (36) the communication.	
1) Responsive to communication(s) filed on 23 /	November 2001		
	nis action is non-final.		
3) Since this application is in condition for allows		ers prosecution as to the marite in	
closed in accordance with the practice under	Ex parte Quayle, 1935 C.D.	. 11, 453 O.G. 213.	
Disposition of Claims			
4) Claim(s) <u>1-10</u> is/are pending in the application			
4a) Of the above claim(s) is/are withdraw	wn from consideration.		
5) Claim(s) is/are allowed.			
6) Claim(s) is/are rejected.			
7) Claim(s) is/are objected to.			
 8) Claim(s) <u>1-10</u> are subject to restriction and/or e Application Papers 	election requirement.		
9) The specification is objected to by the Examine	r		
10) The drawing(s) filed on <u>03 July 2001</u> is/are: a) □		hy the Evaminer	
Applicant may not request that any objection to the			
11) The proposed drawing correction filed on	_ is: a) ☐ approved b) ☐ disa		
If approved, corrected drawings are required in rep		approved by the Examinor.	
12) The oath or declaration is objected to by the Exa			
Priority under 35 U.S.C. §§ 119 and 120			
13) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 1	19(a)-(d) or (f).	
a) ☐ All b) ☐ Some * c) ☐ None of:	· · ·	() () () ()	
1. Certified copies of the priority documents	s have been received.		
2. Certified copies of the priority documents		lication No.	
 3. Copies of the certified copies of the priori application from the International Bur * See the attached detailed Office action for a list of 	ity documents have been red eau (PCT Rule 17.2(a))	ceived in this National Stage	
14) Acknowledgment is made of a claim for domestic			
a) The translation of the foreign language prov			
15) Acknowledgment is made of a claim for domestic	c priority under 35 U.S.C. §§	120 and/or 121.	
ttachment(s)			
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Infor	nmary (PTO-413) Paper No(s) rmal Patent Application (PTO-152)	
Patent and Trademark Office O-326 (Rev. 04-01) Office Acti	ion Summary	Part of Paper No. 9	

Application/Control Number: 09/897,412 Page 2

Art Unit: 1647

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1, 3, 5, and 7, drawn to a method of treatment of cystic fibrosis in a patient comprising administering SEQ ID NO: 10, classified in class 514, subclass 2, for example.
 - II. Claims 2, 4, 6, and 8, drawn to a method of treatment of chronic obstructive pulmonary disease in a patient comprising administering SEQ ID NO: 10, classified in class 514, subclass 2, for example.
 - III. Claim 9, drawn to a composition comprising a secretin receptor ligand together with a least one other compound active against cystic fibrosis, classification dependent upon agent structure.
 - IV. Claim 10, drawn to a composition comprising a secretin receptor ligand together with a least one other compound active against chronic obstructive pulmonary disease, classification dependent upon agent structure.
- 2. The inventions are distinct, each from the other because of the following reasons:
- 3. Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive Inventions that are directed to <u>different</u> methods, restriction is deemed to be proper because these methods appear to constitute patentably distinct inventions for the following reasons: Inventions I and II are directed to methods that are distinct both

Application/Control Number: 09/897,412 Page 3

Art Unit: 1647

physically and functionally, and are not required one for the other. Invention I requires search and consideration of cystic fibrosis, which is not required by Invention II. Invention II requires search and consideration of chronic obstructive pulmonary disease, which is not required by Invention I.

- 4. Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive groups that are directed to <u>different</u> products, restriction is deemed to be proper because these products constitute patentably distinct inventions for the following reasons. Inventions III and IV are directed to products that are distinct both physically and functionally, are not required one for the other, and are therefore patentably distinct. The composition of Invention III is independent and distinct from the product of Invention IV because it is not required to make the composition of Invention III. The composition of Invention IV is independent and distinct from the product of Invention III because it is not required to make the composition of Invention IV.
- 5. Inventions I and each of Inventions III and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the method of Invention I does not recite the use or manufacture of the compositions of Inventions III or IV.
- 6. Inventions II and each of Inventions III and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01).

Application/Control Number: 09/897,412 Page 4

Art Unit: 1647

In the instant case the method of Invention II does not recite the use or manufacture of the compositions of Inventions III or IV.

- 7. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 8. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, separate search requirements, and/or different classification, restriction for examination purposes as indicated is proper.
- 9. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

.

Application/Control Number: 09/897,412

Art Unit: 1647

Page 5

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher James Nichols, Ph.D. whose telephone number is 703-305-3955. The examiner can normally be reached on Monday through Friday, 8:30AM to 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, Ph.D. can be reached on 703-308-4623. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications. The fax phone numbers for the customer service center is 703-872-9305

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

CJN March 4, 2003 Jau J. Kmz

SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600